WO1994005300B1 - Use of rapamycin in the treatment of aids - Google Patents
Use of rapamycin in the treatment of aidsInfo
- Publication number
- WO1994005300B1 WO1994005300B1 PCT/CA1993/000384 CA9300384W WO9405300B1 WO 1994005300 B1 WO1994005300 B1 WO 1994005300B1 CA 9300384 W CA9300384 W CA 9300384W WO 9405300 B1 WO9405300 B1 WO 9405300B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rapamycin
- medicament
- mammal
- body weight
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
The present invention relates to the use of rapamycin or an analog of rapamycin in the manufacture of a medicament for treating, arresting the development or retarding the progression of an HIV infection in an amount sufficient to achieve a reduction in the level of serum p24 antigen; and to the use of rapamycin or analog of rapamycin for treating, arresting the development or retarding the progression of AIDS in a mammal. The invention also relates to a method for treating, arresting the development or retarding the progression of AIDS in a mammal in need thereof by administering to the mammal an amount of rapamycin or analog of rapamycin sufficient to achieve a reduction in the level of serum p24 antigen.
Claims
1. Use of rapamycin in the manufacture of a medicament for treating, arresting the development or retarding the progression of an HIV infection in an amount sufficient to achieve a reduction in the level of serum p24 antigen.
2. The use according to claim 1, wherein said medicament further comprises another anti-HIV agent.
3. The use according to claim 2, wherein said other anti- HIV agent is a reverse transcriptase inhibitor.
4. The use according to claim 3, wherein said reverse transcriptase inhibitor is selected from AZT, d4T, ddC, ddl, 3TC or analogs of 3TC.
5. The use according to claim 4, wherein said reverse transcriptase inhibitor is present in an amount effective to inhibit HIV replication.
6. The use claimed in any one of claims 1 to 5, wherein the medicament is adapted for oral administration.
7. The use claimed in any one of claims 1 to 5, wherein the medicament is adapted for parenteral administration.
8. The use claimed in any one of claims 1 to 5, wherein the medicament is in unit dosage form.
9. The use claimed in any one of claims 1 to 5, wherein said rapamycin is present in said medicament to administer a dose ranging from 0.25 to 500 mg/ g of body weight per day.
22
10. The use according to claim 9, wherein said rapamycin is present in said medicament to administer a dose ranging from 5 to 500 mg/kg of body weight per day.
11. The use according to claim 10, wherein said rapamycin is present in said medicament to administer a dose ranging from 10 to 250 mg/kg of body weight per day.
12. A method for treating, arresting the development' or retarding the progression of AIDS in a mammal in need thereof which comprises administering to said mammal an amount of rapamycin sufficient to achieve a reduction in the level of serum p24 antigen.
13. A method according to claim 12, wherein said rapamycin is administered orally or parenterally.
14. The method according to claim 12, further comprising administering said rapamycin in combination with another anti-HIV agent.
15. The method according to claim 14, wherein said other anti-HIV agent is a reverse transcriptase inhibitor.
16. The method according to claim 15, wherein said reverse transcriptase inhibitor is selected from AZT, d4T, ddC, ddl, 3TC or analogs of 3TC.
17. The method according to claim 16, wherein said reverse transcriptase inhibitor is administered in an amount effective to inhibit HIV replication.
18. The method according to anyone of claims 12 to 17 wherein said rapamycin is administered in a dose ranging from 0.25 to 500 mg/kg of body weight per day.
19. The method according to claim 18, wherein said rapamycin is administered in a dose ranging from 5 to 500 mg/kg of body weight per day.
20. The method according to claim 19, wherein said rapamycin is administered in a dose ranging from 10 to 250 mg/kg of body weight per day.
21. Use of rapamycin for treating, arresting the development or retarding the progression of AIDS in a mammal.
22. A method for treating, arresting the development or retarding the progression of AIDS in a mammal in need thereof which comprises administering to said mammal an anti-HIV effective amount of rapamycin.
24
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU48123/93A AU4812393A (en) | 1992-09-03 | 1993-09-02 | Use of rapamycin in the treatment of aids |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93877492A | 1992-09-03 | 1992-09-03 | |
| US938,774 | 1992-09-03 | ||
| US10282293A | 1993-08-06 | 1993-08-06 | |
| US102,822 | 1993-08-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1994005300A1 WO1994005300A1 (en) | 1994-03-17 |
| WO1994005300B1 true WO1994005300B1 (en) | 1994-04-14 |
Family
ID=26799773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA1993/000384 Ceased WO1994005300A1 (en) | 1992-09-03 | 1993-09-02 | Use of rapamycin in the treatment of aids |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU4812393A (en) |
| WO (1) | WO1994005300A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE42889E1 (en) | 1992-08-25 | 2011-11-01 | G.D. Searle Llc | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| USRE43802E1 (en) | 1992-08-25 | 2012-11-13 | G.D. Searle Llc | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
| CA2171550C (en) | 1993-09-10 | 2008-08-26 | Raymond F. Schinazi | Nucleosides with anti-hepatitis b virus activity |
| US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
| EP1655033A1 (en) | 1995-06-07 | 2006-05-10 | Emory University | Nucleosides with anti-hepatitis B virus activity |
| EP1545539A4 (en) * | 2002-09-13 | 2010-07-07 | Univ Maryland Biotech Inst | COMPOSITIONS FOR INDUCING INCREASED G (B) -CHIMIOKIN LEVELS AND METHODS OF USE THEREOF |
| EP1627048A4 (en) | 2003-05-16 | 2008-10-15 | Univ Maryland Biotech Inst | COMPOSITIONS FOR REGULATING CCR5 EXPRESSION FACTOR CENSOR INSENSITIZATION AND METHODS OF USING THE SAME |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
| US5093338A (en) * | 1991-04-23 | 1992-03-03 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
-
1993
- 1993-09-02 WO PCT/CA1993/000384 patent/WO1994005300A1/en not_active Ceased
- 1993-09-02 AU AU48123/93A patent/AU4812393A/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE42889E1 (en) | 1992-08-25 | 2011-11-01 | G.D. Searle Llc | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| USRE43802E1 (en) | 1992-08-25 | 2012-11-13 | G.D. Searle Llc | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4507323A (en) | Treatment of psychosexual dysfunctions | |
| US4435449A (en) | Treatment of minimal brain dysfunction (MBD) | |
| IE893690L (en) | Treatment of obesity | |
| HK26087A (en) | Method of contraception and pharmaceutical package therefor | |
| KR930007441A (en) | medicine | |
| KR900701282A (en) | Treatment, prevention of ischemic diseases of the heart or brain | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| AU601237B2 (en) | The use of paroxetine to treat pain | |
| RU95117097A (en) | APPLICATION OF DIDESOXY ANALOGUES OF NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS, METHOD OF TREATMENT OF VIRAL INFECTIONS, β-Z-5-FLUOR-2 ', 3'-DIDESOXYCITOSIN AND ITS PHARMACEUTES | |
| KR910700045A (en) | Treatment of HIV-Related Diseases | |
| JP2002528502A5 (en) | ||
| KR930001902A (en) | Method for preparing fatty acid drug | |
| US4425363A (en) | Treatment of tardive dyskinesia in mammals | |
| KR950007848A (en) | Treatment of Anxiety with (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide | |
| WO1994005300B1 (en) | Use of rapamycin in the treatment of aids | |
| PT1027053E (en) | METHOD OF PREVENTION OF NEFROTOXICITY CAUSED BY CYCLOSPORINS AND TACROLIMUS | |
| MY124465A (en) | Reduction of infarct volume using citicoline | |
| KR890004705A (en) | Antiviral agents | |
| EP0362162B1 (en) | Pharmaceutical composition comprising zidovudine and inosiplex or components thereof for the treatment of aids and aids-related syndromes | |
| IE851848L (en) | Propiophenone compound against sexual dysfunction | |
| Rochelle et al. | Potentiation of antihypertensive therapy by use of chlorothiazide | |
| KR910007528A (en) | Use of Benzodiazepines and Phenylpyrylketone Derivatives | |
| JPH0222227A (en) | Treatment of aids with megesterol acetate | |
| WO1992007564A2 (en) | Method of treating demyelinating disease | |
| KR900701301A (en) | Treatment of myelosuppression associated with AIDS |